Table 8 Baseline characteristics of biologic naïve patients using ABT through intravenous drip or subcutaneous injection.
From: Real-world retention rates of biologics in patients with rheumatoid arthritis
ABT | Intraveous drip | Sc injection | p-value |
|---|---|---|---|
Cases (no.) | 21 | 46 | |
Age (years) | 73.6 ± 6.8 | 70.1 ± 11.3 | 0.3660 |
Male rate (%) | 10.0 | 32.0 | 0.2346 |
Body weight (kg) | 51.3 ± 6.9 | 57.2 ± 14.2 | 0.2213 |
BMI | 21.5 ± 2.4 | 23.4 ± 4.7 | 0.2488 |
ACPA positivity (%) | 70.0 | 96.0 | 0.0613 |
RF positivity (%) | 80.0 | 84.0 | > 0.9999 |
MMP3 (ng/ml) | 251.4 ± 270.0 | 337.6 ± 309.4 | 0.4491 |
PSL usage (%) | 60.0 | 52.0 | 0.7233 |
MTX usage (%) | 80.0 | 72.0 | > 0.9999 |
PSL dose (mg/day) | 5.3 ± 2.5 | 5.1 ± 3.2 | 0.7303 |
MTX dose (mg/week) | 6.3 ± 2.0 | 8.0 ± 4.1 | 0.4501 |
csDMARDs usage (no.) | 1.8 ± 0.9 | 1.8 ± 1.1 | 0.8814 |
Disease duration (months) | 14.0 ± 12.7 | 11.8 ± 15.1 | 0.6918 |
CRP (mg/dl) | 1.7 ± 1.3 | 2.2 ± 2.0 | 0.4691 |
ESR (mm) | 62.3 ± 27.7 | 56.2 ± 25.5 | 0.5337 |
KL6 (U/ml) | 306.6 ± 141.1 | 419.7 ± 353.4 | 0.3626 |
